Abstract: Embodiments of the present application provide a spliced display panel and a spliced display device. In the spliced display panel provided by the embodiments of the present application, a second display module is disposed on a non-display surface of a first display module and corresponding to a spliced region.

Abstract: The invention belongs to the pharmaceutical manufacturing field, which relates to a novel process for the preparation of substituted phenylacetic acids derivatives, especially relates to the preparation of 2-(4-(2-oxocyclopentyl)phenyl)propanoic acid. The process for the preparation of the precursor form of loxoprofen which use 1,4-di-halobenzyl compounds or disubstituted benzyl compounds as starting material, is through the substitution reaction of cyclopentanone groups or its precursor compounds. Wherein X is halogen, L1 is a suitable leaving group selected from halogen, OH, OMs, OTs, OTf and the like; L2 is a suitable leaving group selected from halogen, CN, OH, —CH2OH, —CHO, CH3NO2, ester group, —NR4R5, OTf, OTs, OMs, —C?CR6, —C?CR7 and the like, wherein R4, R5, R6, R7 are short chain alkyl groups; Z is cyclopentanone group and its precursor form selected from and the like; R3 is short chain alkyl groups.

Abstract: The present invention is directed to an efficient process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form of formula I wherein R1 and R2 independently denote C1-3-alkyl groups and X? denotes an acid anion, such as the chloride, bromide, tosylate, mesylate or trifluoroacetate anion, with high quality, and a process for synthesis of EGFR tyrosine kinase inhibitors with heterocyclic quinazoline, quinoline or pyrimidopyrimidine core structure, using the acid addition salt I and activated derivatives thereof as intermediates.

Abstract: The present invention is directed to an efficient process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form of formula I wherein R1 and R2 independently denote C1-3-alkyl groups and X? denotes an acid anion, such as the chloride, bromide, tosylate, mesylate or trifluoroacetate anion, with high quality, and a process for synthesis of EGFR tyrosine kinase inhibitors with heterocyclic quinazoline, quinoline or pyrimidopyrimidine core structure, using the acid addition salt I and activated derivatives thereof as intermediates.

Abstract: Disclosed is a method for the synthesis of N—H or N-alkyl 2-propynamides useful as intermediate in the manufacture of pharmaceutically active ingredients.

Abstract: Disclosed is a method for the synthesis of N—H or N-alkyl 2-propynamides useful as intermediate in the manufacture of pharmaceutically active ingredients.